Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
Stage D2 prostate cancer patients with pulmonary metastases and absence of detectable metastases in bones are quite rare and almost always show accompanying favorable and long-term clinical response to hormone therapy. We present a case of a patient with pulmonary metastases caused by prostate cancer who experienced 13-year complete clinical response to GnRH analogues and we discuss the possible implications of host tissue-metastatic cancer cell interactions in pulmonary metastases and clinical response to hormone depletion therapy.
Behrakis
P
P
Department of Experimental Physiology, Medical School of Athens, Greece.
Koutsilieris
M
M
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002064:Buserelin / Q000627:therapeutic use*; D005500:Follow-Up Studies; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D013739:Testosterone; D017430:Prostate-Specific Antigen; D002064:Buserelin